Camellianin A
(Synonyms: 山茶黄酮苷 A) 目录号 : GC35598
Camellianin A 是 A. nitida 叶中主要的黄酮类化合物，具有抗癌活性和抗血管紧张素转换酶 (ACE) 活性。Camellianin A 能抑制人 Hep G2 和 MCF-7 细胞的增殖，诱导细胞 G0/G1 期停滞。
Cas No.:109232-77-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Camellianin A, the main flavonoid in A. nitida leaves, displays anticancer activity and angiotensin converting enzyme (ACE)-inhibitory activity. Camellianin A inhibits the proliferation of the human Hep G2 and MCF-7 cell lines and induces the significant increase of the G0/G1 cell population[1][2].
[1]. Gao H, et al. Anti-proliferative effect of camellianin A in Adinandra nitida leaves and its apoptotic induction in human Hep G2 and MCF-7 cells. Molecules. 2010 May 28;15(6):3878-86. [2]. Liu B, et al. Antioxidant and angiotensin converting enzyme (ACE) inhibitory activities of ethanol extract and pure flavonoids from Adinandra nitida leaves. Pharm Biol. 2010 Dec;48(12):1432-8.
| Cas No. | 109232-77-1 | SDF | |
| 别名 | 山茶黄酮苷 A | ||
| Canonical SMILES | O[C@H]([C@@H](O)[C@@H]1O[C@@](O[C@@H](C)[C@H](O)[C@H]2O)([H])[C@@H]2O)[C@@H](O[C@@H]1COC(C)=O)OC3=C(C4=O)C(OC(C5=CC=C(O)C=C5)=C4)=CC(O)=C3 | ||
| 分子式 | C29H32O15 | 分子量 | 620.56 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.6114 mL | 8.0572 mL | 16.1145 mL |
| 5 mM | 0.3223 mL | 1.6114 mL | 3.2229 mL |
| 10 mM | 0.1611 mL | 0.8057 mL | 1.6114 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quantitation of Camellianin A in HepG2 cells using a high performance liquid chromatography-electrospray ionization tandem mass spectrometric method
Chin J Nat Med 2017 Mar;15(3):234-240.PMID:28411692DOI:10.1016/S1875-5364(17)30040-7.
The present study was designed to develop a sensitive and selective high performance liquid chromatography-tandem mass spectrometric method for the determination of Camellianin A in HepG2 cells. The extraction of Camellianin A was achieved using 15% trichloroacetic acid and then separated on a C18 column interfaced with a triple quadrupole tandem mass spectrometer in multiple reaction monitoring mode. The mobile phase was consisted of methanol-water (0.1% formic acid) (55 : 45, V/V). The total run time was 5.0 min. The method was linear in the concentration range of 0.25-250.0 ng·mL-1. The lower limit of quantification was 0.25 ng·mL-1. The intra- and inter-day relative standard deviations of entire concentration range were less than 9.3%. The proposed HPLC-MS/MS method was successfully applied to detect the intracellular concentration of Camellianin A in HepG2 cells.
Shibi Tea ( Adinandra nitida) and Camellianin A Alleviate CCl4-Induced Liver Injury in C57BL-6J Mice by Attenuation of Oxidative Stress, Inflammation, and Apoptosis
Nutrients 2022 Jul 24;14(15):3037.PMID:35893891DOI:10.3390/nu14153037.
Liver injury is a significant public health issue nowadays. Shibi tea is a non-Camellia tea prepared from the dried leaves of Adinandra nitida, one of the plants with the greatest flavonoid concentration, with Camellianin A (CA) being the major flavonoid. Shibi tea is extensively used in food and medicine and has been found to provide a variety of health advantages. The benefits of Shibi tea and CA in preventing liver injury have not yet been investigated. The aim of this study was to investigate the hepatoprotective effects of extract of Shibi tea (EST) and CA in mice with carbon tetrachloride (CCl4)-induced acute liver injury. Two different concentrations of EST and CA were given to model mice by gavage for 3 days. Treatment with two concentrations of EST and CA reduced the CCl4-induced elevation of the liver index, liver histopathological injury score, alanine aminotransferase (ALT), and aspartate aminotransferase (AST). Western blotting and immunohistochemical analysis demonstrated that EST and CA regulated the oxidative stress signaling pathway protein levels of nuclear factor E2-related factor 2 (Nrf2)/heme-oxygenase-1 (HO-1), the expression of inflammatory cytokines, the phosphorylated nuclear factor-kappaB p65 (p-NF-κB)/nuclear factor-kappaB p65 (NF-κB) ratio, the phospho-p44/42 mitogen-activated protein kinase (p-MAPK), and the apoptosis-related protein levels of BCL2-associated X (Bax)/B cell leukemia/lymphoma 2 (Bcl2) in the liver. Taken together, EST and CA can protect against CCl4-induced liver injury by exerting antioxidative stress, anti-inflammation, and anti-apoptosis.
Pharmacokinetics and tissue distribution study of Camellianin A and its major metabolite in rats by liquid chromatography with tandem mass spectrometry
J Chromatogr B Analyt Technol Biomed Life Sci 2015 Aug 1;997:200-9.PMID:26117310DOI:10.1016/j.jchromb.2015.06.012.
Camellianin A is a major active constituent of Adinandra nitida. A LC-MS/MS method for the determination of Camellianin A and its metabolite (camellianin B) in rat plasma and tissues was developed and applied to a pharmacokinetics and tissue distribution study. Samples were separated on a Waters HSS T3 column with a mobile phase consisted of methanol and water (containing 0.1% formic acid). MS/MS detection was carried out on a triple-quadruple mass spectrometer under negative ESI mode. Pharmacokinetics study showed that Camellianin A was rapidly eliminated with a t1/2 of 92.6±41.4h and CL of 3.19±0.471L/min/kg. Additionally, Camellianin A showed a low oral bioavailability of 2.99% and a narrow tissue distribution; however, camellianin B was proved to have a wide tissue distribution with brain penetration. The data presented in this study provides useful information for the further applications of A. nitida and Camellianin A.
Anti-proliferative effect of Camellianin A in Adinandra nitida leaves and its apoptotic induction in human Hep G2 and MCF-7 cells
Molecules 2010 May 28;15(6):3878-86.PMID:20657414DOI:10.3390/molecules15063878.
Leaves of Adinandra nitida constitute a kind of flavonoid-rich plant food. In this study, Camellianin A, the main flavonoid in the leaves of Adinandra nitida,was prepared and identified by high performance liquid chromatography-photodiode array detector-electrospray ionization mass spectrometry (HPLC-PDA-ESI/MS). In the anticancer assay, it was found Camellianin A could inhibit the proliferation of the human hepatocellular liver carcinoma Hep G2 and human breast adenocarcinoma MCF-7 cell lines in a dose-dependent manner and induce the significant increase of the G0/G1 cell population. After treated by Camellianin A, phosphatidylserine of Hep G2 and MCF-7 cells could translocate significantly to the surface of the membrane. The increase of an early apoptotic population of Hep G2 and MCF-7 cells was observed. It was concluded that Camellianin A not only affected the progress of the cell cycle, but also induced cells to enter into apoptosis.
Synthetic investigation toward apigenin 5-O-glycoside camellianin B as well as the chemical structure revision
Org Biomol Chem 2016 Jun 7;14(21):4842-7.PMID:27145917DOI:10.1039/c6ob00655h.
Capitalizing on the Au(i)-catalyzed ortho-alkynylbenzoate glycosylation method, the first total synthesis of the proposed structure of apigenin-5-O-glycoside camellianin B was achieved, wherein three approaches, one linear and two convergent, were established, through which the synthetic structures were firmly corroborated. Meanwhile, through the synthesis of anthentic camellianin B via commercially available Camellianin A, the misassigned structures of camellianins A and B were revised.